SULFAMETHOXAZOLE AND TRIMETHOPRIM
LOE ApproachingNDAORALTABLET
Approved
May 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SULFAMETHOXAZOLE AND TRIMETHOPRIM by Teva is clinical pharmacology sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. First approved in 1981.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sulfamethoxazole and trimethoprim is a fixed-dose oral combination antibiotic approved in 1981 for treating prosthetic joint infections. It works by blocking two consecutive steps in bacterial nucleic acid and protein synthesis: sulfamethoxazole inhibits dihydrofolic acid synthesis while trimethoprim inhibits dihydrofolate reductase. The synergistic dual mechanism results in slower resistance development compared to either agent alone.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), limiting growth opportunities and likely triggering transition to generic-optimized operations.
Mechanism of Action
CLINICAL PHARMACOLOGY Sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. Sulfamethoxazole is metabolized…
Worked on SULFAMETHOXAZOLE AND TRIMETHOPRIM at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.